Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Revenue (2016 - 2025)

Vanda Pharmaceuticals' Revenue history spans 16 years, with the latest figure at $57.2 million for Q4 2025.

  • On a quarterly basis, Revenue rose 7.58% to $57.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $216.1 million, a 8.72% increase, with the full-year FY2025 number at $216.1 million, up 8.72% from a year prior.
  • Revenue hit $57.2 million in Q4 2025 for Vanda Pharmaceuticals, up from $56.3 million in the prior quarter.
  • Over the last five years, Revenue for VNDA hit a ceiling of $70.1 million in Q3 2021 and a floor of $38.8 million in Q3 2023.
  • Historically, Revenue has averaged $56.5 million across 5 years, with a median of $56.7 million in 2025.
  • Biggest five-year swings in Revenue: crashed 40.58% in 2023 and later grew 22.76% in 2024.
  • Tracing VNDA's Revenue over 5 years: stood at $68.0 million in 2021, then fell by 5.2% to $64.5 million in 2022, then dropped by 29.79% to $45.3 million in 2023, then increased by 17.48% to $53.2 million in 2024, then increased by 7.58% to $57.2 million in 2025.
  • Business Quant data shows Revenue for VNDA at $57.2 million in Q4 2025, $56.3 million in Q3 2025, and $52.6 million in Q2 2025.